Cure My Disease

Don't miss your cure!

 Log in / Sign up

One scan, two images: new MRI technique could cut MS brain exam time

NCT ID NCT07687693

Diagnosis Sponsor: Region Stockholm Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Sep 04, 2026 · Updated 5 times

Summary

This study tests a new MRI technique called ENRAGED FLAIR that aims to capture two types of brain images (T2-FLAIR and T1-weighted) in a single sequence, instead of the usual two separate scans. Researchers will compare the image quality and time savings against standard MRI in 10 adults with multiple sclerosis who are already scheduled for a brain MRI. The extra sequence adds about 5–10 minutes to the exam and uses no additional contrast dye. If it works, this approach could shorten future MRI exams for people with MS while maintaining diagnostic quality.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ENRAGED FLAIR MRI
What this could lead to
If successful, this technique could shorten brain MRI exams for people with multiple sclerosis by combining two scans into one, saving time and improving comfort.
What could go wrong
This is a very small, early study with only 10 participants. The new MRI sequence may not produce images as clear as standard scans, or the time savings may be minimal.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

11 people

The number who actually took part.

Started

Aug 2026

Finished

Aug 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients, 18 years of age or older * Diagnosis of multiple sclerosis * Scheduled for a clinical brain MRI examination including T2-FLAIR and T1-weighted imaging * Able to provide written informed consent Exclusion Criteria: * Age under 18 years * Severe claustrophobia or inability to tolerate the additional MRI acquisition time * Inability to provide written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

Contacts and locations

Locations

  • Karolinska Universitetssjukhuset

    Stockholm, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.